ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 62.2%
Gross margin was 62.2% in Q1 FY2026, up 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 61.8%, up 0.6 pp year over year. Over 3 fiscal years it narrowed by 4.5 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 61.4%
- Year-over-year change
- +0.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.4% | +0.5pp |
| FY2024 | 2024-12-31 | 60.9% | +4.1pp |
| FY2023 | 2023-12-31 | 56.8% | -9.0pp |
| FY2022 | 2022-12-31 | 65.8% | -2.4pp |
| FY2021 | 2021-12-31 | 68.2% | — |
Gross Margin vs competitors
How CLPT compares with its peers on the latest reported figures
- CLPT's LTM Mar 2026 gross margin of 61.8% is the 4th highest of the 9 companies compared; the peer median is 50.1%.
- Its year-over-year change of +0.6 pp is the 3rd highest of 9, against a peer median of +0.1 pp.
- Over three fiscal years its change of -4.5 pp compares with a peer median of -5.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 80.9% | +8.2 pp | -9.0 pp | |
| LTM Mar 2026 | 79.6% | +0.3 pp | -5.7 pp | |
| LTM Mar 2026 | 69.0% | +1.9 pp | -6.1 pp | |
| LTM Mar 2026 | 61.8% | +0.6 pp | -4.5 pp | |
| LTM Mar 2026 | 51.7% | -3.2 pp | -9.7 pp | |
| LTM Mar 2026 | 48.6% | -6.2 pp | -7.9 pp | |
| LTM Mar 2026 | 48.3% | -1.2 pp | +12.0 pp | |
| LTM Apr 2026 | 33.6% | -0.2 pp | +1.4 pp | |
| LTM Mar 2026 | 27.2% | +0.6 pp | +7.6 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding CLPT) | 50.1% | +0.1 pp | -5.9 pp | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.